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【様 式】 
博士論文要旨 
氏名   舟  橋   真  一
論文題名  新規モノクローナル抗体の作製にあたっての 
エピトープの選択と抗体の機能に関する研究
主査  島田 章則 
副査  栗林 尚志 
  荻原 喜久美 
モノクローナル抗体は、その特異性から分子生物学的ならびに病理組織学的な
分子の検出・解析に威力を発揮するとともに、抗体の持つ機能との組み合わせに
より分子標的治療にも広く活用されている。本研究では二つのモノクローナル抗
体の取得について報告する。一報は幹細胞の分子生物学的・病理組織学的研究へ
の展開を目指したモノクローナル抗体の取得に関する研究であり、もう一報は、
そこから得られたナレッジを活用した抗体創薬に向けたモノクローナル抗体の取
得に関する研究である。 
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Ⅰ. LGR6 (Leucine-rich repeat (LRR)-containing G protein-coupled 
receptor) に対するモノクローナル抗体の作製とその性状 
LGR6は Gタンパク質共役受容体（GPCR）の一つで、ロイシン・リッチ・リピー
トを含む GPCR(LGR)ファミリーのメンバーである。LGR6は、LGR4, 5とともに LGR
のサブファミリーを形成し、これらの分子で最も研究が進んでいるのは LGR5であ
る。LGR5は小腸、胃、皮膚の幹細胞、および大腸癌幹細胞のマーカーとして知ら
れており、我々は先の研究で LGR5の発現が大腸癌幹細胞の増殖と静止状態を区別
する分子病理学的マーカーであることを報告した。今回研究を進めた LGR6 も、
genetic lineage tracing の解析から原始の皮膚の幹細胞マーカーとして報告さ
れている。しかし、LGR6 の組織学的な発現情報や LGR6 陽性細胞の機能・役割に
ついては、特異的な抗体が得られていないためにいまだ詳細に解明されていない。
我々が抗 LGR5 抗体を取得する際に経験した困難さから LGR6 特異的抗体が得られ
ていないのは、このサブファミリーに特徴的なタンパクの構造に起因するものと
考えられた。すなわち、LGR サブファミリーは N 末端に馬蹄形をした 500 アミノ
酸からなるロイシン・リッチ・リピート領域を有し、この複雑な立体構造を維持
した免疫抗原を調製することが難しいこと、また、ロイシン・リッチ・リピート
領域を含めサブファミリー分子間の相同性が高く、ファミリー分子に交差しない
特異的抗体の取得が難しいことが考えられた。 
そこで我々はこれらの課題を克服するために、DNA免疫法による LGR6 特異的抗
体の作製を試みた。DNA 免疫法では、金粒子にコーティングした発現プラスミド
を GeneGun によって高圧でマウスの腹部に接種し、発現プラスミドが導入された
細胞ではタンパク質が産生され、これらのタンパク質は立体構造を維持した状態
で細胞膜上に提示され、免疫抗原としてマウスでの抗体産生を誘導することがで
きる。LGR6 発現プラスミドを DNA 免疫法で Balb/c マウスに導入した結果、LGR6
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に対する液性免疫が誘導され、LGR6に対する抗体が産生された。 
LGR6 に対する抗体価が上昇したマウスに対し、さらに LGR6 に対する免疫を亢
進させるためにブースト免疫として LGR6 タンパク質を高発現した細胞株の細胞
免疫を実施した。LGRファミリーを含む GPCRは一般に高発現株を取得することが
難しいとされているが、我々は先の抗 LGR5 抗体取得の際に LGR5 を高発現させる
方法としてマウスProB細胞株であるBa/F3株を使用することが有効であることを
経験していた。Ba/F3 株は目的の遺伝子を発現する細胞株の樹立にあまり広く利
用されていない親株であるが、浮遊細胞のためフローサイトメトリー解析におい
て細胞の調整が容易であり、また細胞の増殖が速いことから細胞株の樹立を早期
に実現できるメリットがある。また、Ba/F3株は Balb/cマウスに由来する細胞株
であり、Balb/cマウスへ免疫する際には Ba/F3株で発現される抗原のみが外来抗
原と認識される。そこで、LGR6高発現 Ba/F3株を樹立し、細胞免疫を施すことで
特異的な免疫増強による抗体価上昇を誘導し、抗 LGR6モノクローナル抗体を取得
することができた。 
取得された抗体については、以下の流れで特性と機能の解析を行った。 
1. LGR6特異的抗体は、フローサイトメトリーを用いて細胞外領域への結合の有
無でエピトープ分類を行い、N末端の細胞外領域（N-ECD）を認識する抗体と
7 回膜貫通領域(7TM)の細胞外ループを認識する抗体のエピトープを確認した。
その結果、N-ECDを認識する抗体２クローンと 7TMを認識する抗体１クローン
を取得した。
2. LGR6特異的抗体による LGR6とリガンド RSPO-1との結合阻害活性を解析した。
RSPO-1の LGR6への結合を検出するため、タグ付きの組換えタンパク質の
RSPO-1を準備し、タグに対する抗体で検出するアッセイ系を構築した。反応
系に加えた抗 LGR6抗体の濃度依存的な結合阻害を評価した。その結果、43A6,
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43D10の二つのクローンは LGR6とリガンド RSPO-1との結合を阻害することが
明らかとなった。 
DNA 免疫と細胞免疫の二つの方法を組み合わせることによって、LGR6 に特異的
であるとともに、リガンドとレセプターの結合を阻害する中和活性のある抗体の
取得にも成功した。これらの成果は、LGR6の立体構造を維持したタンパク質を免
疫抗原として用いたことと、立体構造の維持によりリガンドの結合部位が保存さ
れたという、免疫手法の選択・工夫がもたらしたものと考える。今回取得した抗
体は、LGR6陽性細胞の役割・機能の解明など新たな幹細胞生物学の進展に貢献で
きるものと考える。 
Ⅱ.扁平上皮癌への創薬応用を目指した天疱瘡作用の誘発しない抗デスモグレイ
ン３ (Desmoglein 3 (DSG3))抗体の作製
近年、癌を標的としたモノクローナル抗体が分子標的治療薬として利用されて
きている。抗体をベースとした創薬の特徴は、抗体の特異性と、中和活性、抗体
依存的な細胞傷害活性（ADCC）、補体依存的な細胞傷害活性（CDC）といった抗体
の機能の組み合わせにより癌細胞を死滅させることである。 
癌に対する抗体創薬の新規標的分子は、遺伝子発現の多寡から候補遺伝子を絞
り込む遺伝子発現解析と、その遺伝子から発現されるタンパク質の組織分布や細
胞膜に位置しているかといった細胞内分布を解析する病理解析の両面から評価さ
れる。これらの解析から、我々は DSG3を重層扁平上皮癌に対する有望な標的分子
として見出した。DSG3 は一回膜貫通タンパク質で他のカドヘリン分子である DSG1
とともにデスモソームを形成し、重層扁平上皮組織での細胞間結合に寄与してい
る。 
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抗 DSG3 自己抗体は皮膚粘膜の水疱を特徴とする自己免疫疾患の一つである天
疱瘡の原因となることが知られている。DSG3を標的とする創薬を進めるためには、
天疱瘡様病変の誘発を回避し、かつ、重層扁平上皮癌に対して薬理作用を発揮し
なければならない。これまでの研究より天疱瘡を引き起こす病原性の自己抗体は、
Ca2+依存的な構造をとる DSG3を認識すること、自己抗体が認識する領域が N末端
の接着界面に存在することが報告されている。これらの知見より、Ca2+非依存的
に DSG3 に結合する抗体を取得することで副作用を回避した治療用抗体を取得で
きるものと仮説を立てた。 
そこで、各種スクリーニング系を駆使し、目的とする特徴を有する抗体の取得
を試みた。スクリーニング系では、DSG3が生体内で本来形成している構造に近い
タンパク質を準備し、エピトープの分類による抗体の選別を行った。抗マウス
DSG3抗体のスクリーニング過程を以下に示す。 
1. マウス DSG3に結合する抗体をフローサイトメトリーによりスクリーニング
した。34個のマウス DSG3結合抗体を取得した。 
2. 癌細胞の死滅誘導方法として ADCCを薬理作用に持つ抗体 12クローンを選抜
した。マウスの ADCC活性を測定する安定したアッセイ系がないため、ヒト
NK92細胞を遺伝子工学的に改変した細胞株を用いたスクリーニング系を考案
し、マウスとヒトの FcRγⅢa融合タンパク質を発現させることによって NK
細胞によるマウス抗体の ADCC活性を測定できる系が構築できた。 
3. 抗体によって DSG3の Ca2+ 依存的構造が認識されるかどうかを Ca2+のキレー
ト剤である EDTA存在下でフローサイトメトリーを用いて評価した。3クロー
ンが Ca2+非依存的に DSG3に結合する抗体であった。そのうち最も結合アフィ
ニティ―の高いクローン 18-1を選定した。 
4. 天疱瘡様病変を誘発する抗体は、細胞間の接着を分離する活性を有している
ことからマウス由来の皮膚細胞シートを用いたスクリーニング方法により抗
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体が細胞の接着機能を阻害する能力があるかどうかを判断した。クローン
18-1は細胞間接着の分離活性は有していなかった。
上記スクリーニング系でマウス DSG3 に対する副作用の回避が可能と考えられ
る抗体 18-1を取得できた。次に、in vivoモデルでの解析として、DSG3 を発現す
るマウス肺癌細胞株 LC12を移植したマウスによる抗腫瘍効果を評価した。その結
果、抗マウス DSG3 抗体 18-1の投与による天疱瘡様病変はみられず、LC12癌組織
の退縮が観察された。副作用を誘導するエピトープを避け、ADCCを誘導するエピ
トープを選択することにより DSG3 に対する創薬抗体の作製が可能であることが
マウスモデル系で示された。
次に、同様のスクリーニングフローを用い、ヒト DSG3に対し天疱瘡様病変の誘
発作用がなく、高い ADCC作用を持つ抗体 DF366を取得した。種々のヒト重層扁平
上皮癌担癌モデルでの抗ヒト DSG3抗体 DF366の抗腫瘍効果を確認し、抗体医薬と
しての可能性を示した。 
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Ⅲ. 総括 
 
二つの解析から目的のエピトープを持つ抗体を作製するための要点は次にあげ
る二点となる。一つは、免疫やスクリーニングに用いるタンパク質は機能的に天
然の構造を持ったものを利用することであり、もう一つは、エピトープを分類す
ることで適切な抗体の機能を付加できるような抗体の分類をすることである。こ
れらのステップは目的の機能を持った抗体を同定・取得する有用なアプローチを
提供するものである。 
現在、抗体創薬標的分子は枯渇している。今回、医薬品とするためには不都合
な作用のある抗原であってもエピトープの選択次第で新しい創薬への展開が可能
となることを示唆した。この研究は、分子標的薬としての抗体創薬の標的分子の
選択可能性を広げるものであり、今後の抗体医薬品の研究開発に貢献するものと
考える。 
 
本論文の一部は以下に公表した。 
 
1. Generation and characterization of monoclonal antibodies against human 
LGR6. 
Funahashi SI, Suzuki Y, Nakano K, Kawai S, Suzuki M. 
“This is a pre-copyedited, author-produced version of an article accepted for 
publication in The Journal of Biochemistry following peer review. The 
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available online at: https://doi.org/10.1093/jb/mvw077”                       
 
2. Generation of an anti-desmoglein 3 antibody without pathogenic activity of 
pemphigus vulgaris for therapeutic application to squamous cell carcinoma 
Funahashi SI, Kawai S, Fujii E, Taniguchi K, Nakano K, Ishikawa S, 
Aburatani H, Suzuki M. 
The Journal of Biochemistry (2018) 164(6): 471-481.  
https://doi.org/10.1093/jb/mvy074 
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A study on the effectiveness of combinationing epitope selection and 
antibody function for the generation of novel monoclonal antibodies 
 
Abstract: 
 
Monoclonal antibodies are considered powerful tools for molecular 
biological or histopathological detection and analysis of a molecule due to their 
specificity, and they are also widely utilized for molecular targeted therapy by 
combining their specificity and functionality. 
In the current research the process of the generation of two unique 
monoclonal antibodies was studied. With the first antibody, the process of 
obtaining a monoclonal antibody aimed for application to molecular biological 
or histopathological analysis in stem cell research is studied, and for the 
second, the knowledge obtained in the process for the first antibody is applied 
for development of an antibody therapy. 
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I. Generation and characterization of monoclonal antibodies against 
human LGR6 (Leucine-rich repeat (LRR)-containing G 
protein-coupled receptor)  
 
LGR6 is a G protein-coupled receptor (GPCR) and a member of the 
LRR containing GPCR (LGR) family. LGR4, 5 and 6 belong to the same 
subfamily and one of the best studied is LGR5. LGR5 is known as a marker of 
intestinal, gastric, skin and also colon cancer stem cells. We previously 
reported that LGR5 expression could be used as a molecular pathological 
marker to distinguish the states of proliferating and quiescent cancer stem 
cells. LGR6 is also known as a marker for primitive epidermal stem cells from 
genetic lineage tracing analysis. However, information concerning its 
histological expression, cellular functions and physiological roles of is scarce 
due to the lack of a specific antibody. From our previous experience in 
obtaining an LGR5 antibody, we judged that we would face similar difficulties 
with an LGR6 antibody because of the complex structure of LGR proteins. 
LGRs have about 500 amino acids’ length of LRR region with a horseshoe 
structure in the N-terminus and this complex tertiary structural feature 
makes it a challenge to prepare immunogen. In addition, it is difficult to 
obtain antibodies that do not cross-reactive to other LGRs because of high 
homology between subfamily molecules with the LRR region.  
Thus we attempted to generate a LGR6-specific antibody by DNA 
immunization to overcome these problems. For DNA immunization gold 
particles coated with plasmids expressing the molecule of interest are 
prepared. The particles are injected into the abdominal skin of mice with a 
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high pressured GeneGun inducing the protein encoded in the plasmids. The 
protein is displayed on the plasma membrane with a native tertiary structure, 
and was thought to be a robust immunogen for induction of humoral antibody 
production in mice. By introducing a plasmid expressing the LGR6 gene in 
Balb/c mice we succeeded in inducing a humoral immune response to obtain 
antibodies against LGR6. 
Furthermore, to enhance immunity against LGR6, we additionally 
injected a cell line overexpressing LGR6 as a boosting immunogen into the 
mice that were immunized by the plasmids with high titers of anti-LGR6 
antibodies. Although, it is generally a challenge to obtain a stable cell line 
overexpressing GPCRs including the LGR family proteins, we found in our 
experience with LGR5 that it is effective to use the mouse proB cell, Ba/F3 cell. 
Ba/F3 is not frequently used for the establishment of cell lines with specific 
gene expression. However this cell line is a floating cell that can be analyzed 
easily by flow cytometry and because of its rapid growth, the establishment of 
a cell line can be accomplished in a short time. As Ba/F3 is derived from Balb/c 
mice, human antigens expressed in Ba/F3 cells, can be recognized specifically 
as a foreign antigen when injected into Balb/c mice. By this method, 
LGR6-specific immunity was augmented, making it easier to obtain 
monoclonal antibodies against LGR6. 
According to the following flow, the characteristics and functions of 
the monoclonal antibodies against LGR6 obtained with the above methods 
were analyzed. 
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1. Epitope classification was carried out by identifying binders to the 
N-terminal extracellular domain (N-ECD) or 7-pass transmembrane 
domain (7TM) of LGR6 by flow cytometry. As a result, we obtained three 
clones, 43A6 and 43D10, with an epitope against N-ECD and 43A25 
against 7TM. 
2. The inhibitory activity of the antibodies against ligand binding to LGR6 
was evaluated. It is well known that RSPO1 is a ligand that binds to the 
N-ECD of LGR6. Recombinant RSPO1 with a myc-His tag was prepared 
and an assay system for detection of RSPO1-bindig to LGR6 was 
established with an anti-myc tag antibody. Binding inhibition dependent 
on antibody concentration was evaluated. As a result, 2 clones, 43A6 and 
43D10, were found to inhibit binding of ligand to LGR6. On the other 
hand, 43A25 did not inhibit RSPO1-binding. 
 The key to our success with the LGR6 antibodies was thought to be 
the selection of the immunization method of combining DNA and cell 
immunization which enabled immunization with an immunogen preserving 
the native tertiary structure of the ligand binding site of LGR6.  
Utilizing our unique antibodies may lead to understanding the role 
and function of LRG6-positive cells, and we anticipate that this may 
contribute to the progress in stem cell research.   
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II. Generation of anti-desmoglein 3 (DSG3) antibody without
pathogenic activity of pemphigus vulgaris for therapeutic
application to squamous cell carcinoma
In the second report, therapeutic application of an anti-DSG3 
monoclonal antibody is studied. Cancer-targeted monoclonal antibodies are 
frequently utilized in cancer therapy. The advantage of antibody-based 
therapeutics is their specificity and functionality such as neutralization, 
antibody-dependent cell-mediated cytotoxicity (ADCC), or 
complement-dependent cytotoxicity (CDC), by which the antibody can 
eliminate cancer cells. Many therapeutic antibodies against cancer have been 
launched and there have been great benefits for the therapeutic modality in 
the oncology field. 
Prior to our second study, candidate genes with high gene expression 
levels in tumor tissues compared to normal tissues were selected in order to 
discover a novel drug target for antibody therapy in cancer patients The tissue 
distribution of the gene product and their subcellular localization to the cell 
membrane in tumor tissues was studied to confirm the protein expression. By 
this process we found that DSG3 is a promising target for squamous cell 
carcinoma. DSG3 is a one-pass transmembrane protein and forms 
desmosomes along with another desmosomal cadherin, DSG1, and contributes 
to cell-cell adhesion in stratified squamous tissues.  
It is well known that anti-DSG3 autoantibodies cause PV, an 
autoimmune disease characterized by cutaneous and mucosal blistering. To 
successfully target DSG3 for therapy, it is necessary to avoid PV-like effects 
and exert pharmacological action against squamous carcinoma cells. It is 
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reported that pathogenic autoantibodies which induce PV recognizes a 
Ca2+-dependent structure of DSG3 and the region bound by 
DSG3-autoanibodies is located in the N-terminal adhesive interface. From 
these findings, we hypothesized that a therapeutic antibody with no severe 
side effects could be generated by obtaining antibodies that bind DSG3 in 
Ca2+-independent manner. 
Thus, we attempted to obtain such an antibody by using several 
screening systems. In the screening system we prepared proteins mimicking 
the native conformation of DSG3 and selected antibodies by epitope 
classification. Our screening process is shown below. 
 
1. Antibodies with the ability to bind mouse DSG3 were selected by flow 
cytometry. 34 clones were found to bind mouse DSG3.  
2. We selected ADCC as the pharmacological action of antibodies, and 12 
antibodies with ADCC function through the following screening system. 
To construct a stable assay for ADCC activity, we designed a screening 
system using genetically engineered NK cells. We established an ADCC 
assay system with human NK92 cells expressing a chimeric protein with 
the ECD of mouse FcγRIIIa fused to the human transmembrane and 
cytoplasmic domain of FcγRIIIa.  
3. Recognition of the Ca2+ dependent structure of DSG3 was evaluated by 
flow cytometry under the presence of an EDTA, a Ca2+ chelator. Three 
clones were found to bind DSG3 in Ca2+-independent manner. Clone 18-1 
that had the highest binding- affinity to mouse DSG3 was selected as the 
final candidate. 
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4. Screening with keratinocyte sheets is used to judge the ability of
interference to adhesive function by antibodies, as the antibody which
could induce PV-like lesion has dissociating activity to cell-cell adhesion.
We tested clone 18-1 on the keratinocyte sheets and found there was no
dissociating activity.
By this screening system an antibody with no severe side effects, 18-1, 
was obtained. Next, anti-tumor activity was evaluated in mice subcutaneously 
inoculated with a mouse lung cancer cell line LC12 overexpressing DSG3. 
Consequently PV-like changes were not observed in mice and the tumor was 
regressed by anti-mouse DSG3 antibody administration. The results show 
that it is possible to generate a therapeutic antibody against DSG3 by 
selecting an ADCC-promoting epitope that can be distinguished from an 
epitope inducing pathogenic response. 
Next, along with the same screening flow used in generating the 
anti-mouse DSG3 antibody, an anti-human DSG3 antibody with high ADCC 
activity DF366 that does not induce PV-like lesions, was successfully 
generated. The potential of the DF366 antibody as a therapeutic was shown by 
the efficacy in xenograft models of various human squamous cell carcinomas. 
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III. Summary 
 
The essential points for generating antibodies with an intended 
epitope are 1) the utilization of protein with functional and native 
conformation for in vivo immunization and screening, and 2) to confirm 
adequate function by epitope classification. These steps present a useful 
approach to identify and generate an antibody with intended function. 
Currently, promising target molecules for antibody therapeutics are 
said to be exhausted. It was suggested in the second report that there is a 
potential for developing a novel therapeutic antibody in the choice of epitope, 
even if the antigen has a concern of unwanted effects as a therapeutic target. 
The current study may expand the option for selecting antibody-based drug 
targets, and is thought to contribute to the research and development for the 
future antibody therapeutics.  
A part of this thesis was published below.   
1. Generation and characterization of monoclonal antibodies against human 
LGR6. 
Funahashi SI, Suzuki Y, Nakano K, Kawai S, Suzuki M. 
“This is a pre-copyedited, author-produced version of an article accepted for 
publication in The Journal of Biochemistry following peer review. The 
version of record [The Journal of Biochemistry (2017) 161(4): 361-368] is 
available online at: https://doi.org/10.1093/jb/mvw077”                        
 
2. Generation of an anti-desmoglein 3 antibody without pathogenic activity of 
pemphigus vulgaris for therapeutic application to squamous cell carcinoma 
Funahashi SI, Kawai S, Fujii E, Taniguchi K, Nakano K, Ishikawa S, 
Aburatani H, Suzuki M. 
The Journal of Biochemistry (2018) 164(6): 471-481.  
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Leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6) is a seven-pass transmembrane 
protein known to be a marker of stem cells in several organs. To understand the cell biology of 
LGR6-positive cells, including stem cells, we generated monoclonal antibodies (mAbs) against 
human LGR6. DNA immunization followed by whole-cell immunization with LGR6-expressing 
transfectants was performed to obtain mAbs that recognized the native form of LGR6. Hybridomas 
were screened by flow cytometry using LGR6-transfected cells. Because the molecules of LGR4, 
LGR5, and LGR6 are 50% homologous at the amino acid level, specificity of the mAbs was 
confirmed by transfectants expressing LGR4, LGR5, or LGR6. Three LGR6-specific mAbs were 
generated. Two of the three mAbs (designated 43A6 and 43D10) recognized the large N-terminal 
extracellular domain of LGR6, and competitively blocked the binding of R-spondin 1, which is 
known to be the ligand for LGR6. The other mAb, 43A25, recognized the seven-pass 
transmembrane domain of LGR6, and was able to be used for immunoblot analysis. In addition, 
mAbs 43A6 and 43D10 detected endogenous expression of LGR6 in cancer cell lines. We expect 
that our mAbs will contribute to further understanding of LGR6-positive cells in humans. 
Keywords: flow cytometry/LGR6/monoclonal antibody/R-spondin/stem cell marker 
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Leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6) is a member of the type-B 
LGR subfamily consisting of LGR4, LGR5, and LGR6 (1, 2). A structural feature of this subfamily 
is a large N-terminal extracellular domain (ECD) composed of 17 leucine-rich repeats (LRRs). 
LGR6 shares nearly 50% identity with LGR4 and LGR5 at the amino acid level (3). These 
molecules bind to R-spondins (RSPOs) through the N-terminal ECD and regulate Wnt signaling 
(4-8). 
LGR6 is reported to be a stem cell marker in some organs. By mouse lineage tracing 
experiments, it was discovered that LGR6 is expressed in a tight cell cluster at the isthmus of the 
hair follicle in skin and that cells in this cluster could generate all skin components, including hair 
follicles, sebaceous glands, and interfollicular epidermis, in adult mice (9, 10). Recently, it has also 
been shown in mice and humans that LGR6-positive cells have stem cell properties in lungs, teeth, 
cochlea, and taste buds (11-17). To extend this knowledge from mouse experiments to humans, 
well-validated specific antibodies against LGR6 are mandatory. However, it is generally considered 
that generation of antibodies against GPCRs including those of the LGR family is difficult because 
of their low levels of expression and complex conformation (18, 19). 
Previously, we compared various immunization methods to obtain monoclonal antibodies 
(mAbs) against LGR5 (20), which is known to be a marker of intestinal stem cells and colon cancer 
stem cells (21, 22). By combining DNA immunization and whole-cell immunization, we 
successfully generated antibodies suitable for use in flow cytometry . By using these antibodies, we 
could sort LGR5-positive cells from colon cancer tissues and could characterize their cancer stem 
cell features such as high-tumor initiating activity (20). 
In the current study we attempted to generate human LGR6 antibodies by adapting the methods 
we had previously successfully used for LGR5 antibodies (20). As a result, we obtained 
LGR6-specific antibodies suitable for use in flow cytometry and for immunoblotting. Since to the 
best our knowledge there are no other specific antibodies against LGR6, it is expected that our 
antibodies will contribute to further understanding of biological insights into LGR6-positive cells in 
humans. 
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Materials and Methods 
DNA constructs 
LGR6 cDNA (RefSeq: NM_001017403) was PCR-amplified from Kuramochi cells. Human LGR4 
(RefSeq: NM_018490), LGR5 (RefSeq: NM_003667), and LGR6 genes were cloned in pCOS2 
vector and expressed under EF1α promoter (23). For LGR4, 24 amino acids of the signal sequence 
of LGR4 were replaced with the signal sequence of bovine prolactin and an HA-tag was attached to 
the N-terminal. For analysis of the binding regions of LGR6 antibodies, full-length LGR6 and LGR6 
∆1–444 (deleted aa 1–444) were cloned in oriP/EBNA-1 episomal vector. Human RSPO1 cDNA 
(RefSeq: NM_001242908) was PCR-amplified from HCC1419 cells and cloned into episomal vector 
with a myc-His tag in the C-terminal. 
Cell culture and transfection 
Mouse pro-B cell line Ba/F3 was purchased from Riken Cell Bank (Tsukuba, Japan) and cultured in 
RPMI-1640 medium containing 10% fetal calf serum in the presence of 1 ng/mL IL-3. Ba/F3 cell 
lines expressing HA-LGR4, LGR5, and LGR6 were established by electroporation with the plasmids 
carrying each of the LGR genes. These cell lines were selected by 500 µg/mL geneticin (Life 
Technologies, Tokyo, Japan). The full-length LGR6 and deletion mutant plasmid were transfected in 
FreeStyle 293F cells by using FreeStyle Max reagent (Life Technologies). Cells were cultured for 
2 days in FreeStyle Expression Medium (Life Technologies) after transfection and were analyzed by 
flow cytometry. Mouse myeloma cell line P3-X63Ag8U1 was obtained from ATCC (Manassas, VA) 
and the cells were used as partner cells in hybridoma generation. Cancer cell lines AsPC-1, SW620, 
LoVo, Capan-1, PANC-1, HT-29, AGS, and HCC1419 were obtained from ATCC. Kuramochi cells 
were obtained from JCRB (Tokyo, Japan) and HCT 116 cells were obtained from ECACC 
(Salisbury, UK). Cell culture was done according to the vendors’ instructions.
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Animals 
6-week-old Balb/c mice were purchased from Nihon Charles River (Kanagawa, Japan). Care and use 
of animals used in this study was in accordance with the Guidelines for the Care and Use of 
Laboratory Animals at Forerunner Pharma Research Co., Ltd. under the approval of the company’s 
Institutional Animal Care and Use Committee. 
Generation of antibodies 
To obtain monoclonal antibodies (mAbs) against LGR6, DNA immunization (24) and whole-cell 
immunization was performed. DNA immunization was performed by the Helios Gene Gun System 
(Bio-Rad, Hercules, CA), with plasmid LGR6/pCOS2 coated onto 1-µ  gold particles (Bio-Rad); 
the plasmid-coated gold particles were introduced into the abdominal epidermis of 6-week-old 
Balb/c mice. After eight gene-gun deliveries, when the serum titer of anti-LGR6 antibodies had 
increased, the mice were administered booster immunization with 2 × 10
6
 cells of LGR6_Ba/F3. 
Splenocytes were isolated and fused with P3-X63Ag8U1 by the polyethylene glycol method (25). 
The resulting hybridomas were selected by culturing in hypoxanthine/aminopterin/thymidine (HAT) 
medium. The supernatant was screened by flow cytometry with LGR6_Ba/F3. Positive hybridomas 
were cloned by the limited dilution method. The mAbs were purified by HiTrap Protein G column 
(GE Healthcare, Tokyo, Japan). Isotyping was done with IsoStrip Mouse Monoclonal Antibody 
Isotyping Kit (Roche Diagnostics, Tokyo, Japan). 
Flow cytometry analysis 
Cells were harvested and washed with FACS buffer (2% BSA/PBS/0.05% NaN3), and incubated 
with mAb at 4°C for 30 min. Then, the cells were washed with FACS buffer and stained with goat 
F(ab′)2 fragment anti- ouse IgG (Fc gamma) labeled with FITC, PE, or APC (BD Bioscience, San 
Jose, CA) at 4°C for 1 h. Prior to analysis, dead cells were labeled with viability dye 7-AAD 
(Beckman Coulter, Tokyo, Japan) or DAPI (4′,6-diamidino-2-phenylindole). Flow cytometry was 
performed using FACSCalibur (BD Bioscience) or FACSAria III (BD Bioscience). Flow cytometry 
data were analyzed using CellQuest software (BD Bioscience) and FlowJo (Tree Star, Ashland, OR). 
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The geometric values (geomean) values of flow cytometry analysis were plotted against the 
concentrations of antibodies. Graphs were drawn and EC50 values were estimated with GraphPad 
Prism (GraphPad Software, San Diego, CA). Anti-LGR5 antibody 2L36 was generated in our 
previous study (20). HA-tag antibody (HA-7) was purchased from Sigma-Aldrich (St. Louis, MO). 
Immunoblot analysis 
Whole-cell lysate was prepared with lysis buffer (0.5% NP-40/20 mM Tris-HCl [pH 8]/150 mM 
NaCl) with Complete Mini Protease Inhibitor (Roche Diagnostics). A 1 µg quantity of lysate was 
separated by a 4%–20% gradient SDS-PAGE and transferred to PVDF membrane (Millipore, Tokyo, 
Japan). Blotted protein was detected with mouse mAbs and anti- ouse IgG horseradish peroxidase 
conjugate (GE Healthcare). Signals were detected using the ECL Prime Western Blotting Detection 
System (GE Healthcare) with imaging on an ImageQuant LAS-4000 system (Fujifilm, Tokyo, 
Japan). For immunoblot detection of LGR5, anti-LGR5 antibody 2U1E-1 was used. The antibody 
2U1E-1 was established in our previous work (20). 
Real-time PCR 
Total RNA was isolated with an RNeasy Mini Kit (Qiagen, Tokyo, Japan). Real-time PCR (qPCR) 
analysis of LGR6 mRNA was performed using a StepOnePlus Real-Time PCR System (Applied 
Biosystems, Foster City, CA) with the following primers: LGR6F: 5′-ggcgggacagaacctctc-3′ and 
LGR6R: 5′-tgaggttgttcatgctgaggt-3′. Relative expression values were calculated using the 2
−∆∆CT 
 ethod (26). Beta-actin was used as a reference. 
Small interfering RNA (siRNA) 
LGR6 Stealth siRNA (HSS127002) was purchased from Life Technologies and introduced into 
AsPC-1 cells by reverse liposome transfection (lipofection) using Lipofectamine RNAiMAX 
transfection reagent (Life Technologies). Briefly, 30 pmol siRNA was mixed with RNAiMAX 
reagent and Opti-MEM medium (Life Technologies) directly in 6-well plates, and 2.5 × 10
5
 AsPC-1
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cells were then added. The transfection mix was then incubated for 48 h at 37°C in a CO2 incubator. 
Cells were collected for RNA preparation and flow cytometry analysis. 
Epitope analysis by competition assay 
Antibodies 43A6, 43A25, and 43D10 were labeled (Alexa-488–labeled) with Alexa Fluor 488 
Monoclonal Antibody Labeling Kit (Life Technologies). Competition assay was done as follows: 2 × 
10
5
 cells of LGR6_Ba/F3 were first incubated with an unlabeled antibody at 30 µg/mL for 60 min at 
4°C and then incubated similarly with an Alexa-488–labeled antibody at 1 µg/mL. The cells were 
analyzed by flow cytometry as described above. 
Competition assay for RSPO1 binding 
Recombinant RSPO1- yc-His was expressed in FreeStyle 293F cells in FreeStyle 293 Expression 
Medium (Life Technologies) and purified with HisTrap FF column (GE Healthcare). In the RSPO1 
binding assay, Ba/F3 transfectants and parental Ba/F3 cells were incubated with RSPO1- yc-His on 
ice for 2 h, then with anti- yc PE conjugate (9E10) (R&D Systems, Minneapolis, MN) on ice for 
1 h. The cells were analyzed by flow cytometry. In the competition assay, LGR6_Ba/F3 and 
LGR5_Ba/F3 were pre-incubated with anti-LGR6 or anti-LGR5 antibody; they were then incubated 
with RSPO1- yc-His and analyzed by flow cytometry. 
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Results 
Generation and flow cytometric analysis of anti-LGR6 mAbs 
To generate anti-LGR6 mAbs suitable for use in flow cytometry, we adopted a strategy of DNA 
immunization followed by whole-cell immunization together with screening of hybridomas with 
flow cytometry. 
We first established stable cell lines expressing LGR6 to use in whole-cell immunization and 
screening. We attempted to express LGR6 in commonly used host cells, but we failed to obtain high 
levels of LGR6 expression with CHO and HEK293 cells. Therefore, we transfected LGR6 cDNA 
into the mouse pro-B cell line Ba/F3. LGR6 was efficiently expressed on the cell surface of the 
transfected Ba/F3 cells. To analyze the selectivity of the hybridomas, we also prepared LGR4- and 
LGR5-expressing transfectants using Ba/F3 cells. LGR5 expression was confirmed by 
LGR5-specific antibody 2L36 as we reported previously (20). Because mouse LGR4 is expressed 
endogenously in Ba/F3 cells, HA-tagged human LGR4 was introduced and its expression was 
confirmed by anti-HA-tag mAbs. 
Next we performed DNA immunization of Balb/c mice by using a gene gun system, followed by 
whole-cell immunization with LGR6-expressing transfectants. Nineteen hybridomas were selected 
by flow cytometry screening. We further analyzed the binding selectivity of the antibodies with 
LGR4- or LGR5-expressing Ba/F3 cells. Monoclonal antibodies selected were 43A6, 43A25, and 
43D10, which bound to LGR6-expressing Ba/F3 but not to parent Ba/F3 or to LGR4- or 
LGR5-expressing transfectants (Fig. 1A). 
The isotypes of LGR6-specific mAbs 43A6, 43A25 and 43D10 were IgG1/κ, IgG2a/κ and 
IgG1/κ, respectively. These mAbs bound to LGR6 transfectants in a dose-dependent manner, and the 
EC50 values were 664.8 ±174.5, 1438.3 ±392.0 and 630.9±185.8 ng/mL, respectively, for 43A6, 
43A25 and 43D10 (mean ± SD) (Fig. 1B). 
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Detection of LGR6 endogenously expressed on the cell surface of various cell lines 
Generally, the expression levels of most GPCR proteins including those of the LGR family are not 
so high. Therefore, we investigated whether the anti-LGR6 mAbs could detect endogenous LGR6 
expressed in various cell lines. LGR6-expressing cell lines were searched for in the expression 
profile database of the Cancer Cell line Encyclopedia (CCLE) (http://www.broadinstitute.org/ccle), 
and pancreatic cancer cell line AsPC-1 and colorectal cancer cell line SW620 were selected. Then 
we analyzed the LGR6 expression in nine cell lines, including AsPC-1 and SW620, by qPCR. 
AsPC-1 and SW620 showed comparatively high expression of LGR6 at the mRNA level (Fig. 2A). 
When the anti-LGR6 mAbs were applied to these two cell lines, 43A6 and 43D10 were shown to 
bind to AsPC-1, but binding was not detected with 43A25 (Fig. 2B). The binding of 43A6 and 
43D10 with respect to SW620 was minimal, reflecting the lower expression of LGR6 mRNA in 
SW620. 
Next we performed a knockdown experiment by LGR6 siRNA to confirm whether the binding 
of 43A6 and 43D10 to AsPC-1 was dependent upon the specific binding to LGR6. At 2 days after 
lipofection with siRNA, expression of LGR6 mRNA was assessed by qPCR. A significant decrease 
(78% decrease) in LGR6 was observed at the mRNA lev l (data not shown). After introducing the 
siRNA into AsPC-1 cells, the binding of 43A6 and 43D10 was not detected (Fig. 2C). These results 
indicated that 43A6 and 43D10 could detect endogenously expressed LGR6 specifically. 
Immunoblot analysis with anti-LGR6 mAbs 
In addition, we also screened for mAbs able to be used for immunoblot analysis. Using the cell 
lysate of LGR6-expressing Ba/F3 transfectants, 43A25 clearly detected a band of approximately 
100 kDa and a band exceeding 200 kDa (Fig. 3), whereas the other antibodies did not (data not 
shown). The molecular weight of LGR6 matched the 100 kDa band detected by 43A25, which 
corresponds to a monomer of LGR6, and the other ≥200 kDa band might be a dimer of LGR6. 
Expression of LGR4 and LGR5 in Ba/F3 transfectants was confirmed with anti-HA-tag mAb and 
anti-LGR5 mAb 2U1E-1, respectively (Fig. 3). Because 43A25 did not detect corresponding bands 
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in the blots of the LGR4 and LGR5 transfectants or the parent Ba/F3 cells, it confirms that this clone 
detects LGR6 specifically with immunoblotting. The 43A25 could not detect the low levels of 
endogenous expression of LGR6 in the whole-cell lysate of AsPC-1 (data not shown). 
Characterization of the binding regions of anti-LGR6 mAbs 
We classified the mAbs that were suitable for use in flow cytometry by their binding regions on 
LGR6. Because members of the LGR family have large N-terminal ECDs and seven-pass 
transmembrane (7TM) domains, we constructed an ECD deletion mutant of LGR6 (LGR6 ∆1–444). 
Transient expression of the deletion mutant in 293F cells was used for this analysis, because stable 
transfection of the deletion mutant was not obtained in Ba/F3 cells. As shown in Figure 4A, 43A25 
bound to both ∆1–444 deletion mutant LGR6 and full-length LGR6, but 43A6 and 43D10 only 
bound to full-length LGR6. These results suggest that 43A25 recognized extracellular loops in the 
7TM domain, and 43A6 and 43D10 recognized the N-terminal ECD. 
We further analyzed the vicinity of epitopes of 43A6 and 43D10, both of which recognize the 
N-terminal domain of LGR6. Competition flow cytometry was carried out by analyzing whether
mAbs labeled with Alexa-488 could bind to LGR6_Ba/F3 pre-incubated with an excess amount of 
another unlabeled antibody. Alexa-488–labeled 43A6 bound to LGR6_Ba/F3 pre-treated with 
unlabeled 43D10 (Fig. 4B, center of top panel). Alexa-488–labeled 43D10 also bound to 
LGR6_Ba/F3 pre-treated with unlabeled 43A6 (Fig. 4B, left of middle panel). When the Alexa-488–
labeled mAbs were applied to the cells pre-incubated with the same unlabeled antibody, the binding 
was blocked. These results indicate that the epitopes of clones 43A6 and 43D10 are not identical in 
the N-terminal ECD. In addition, 43A25, which recognized the 7TM domain of LGR6, did not 
compete for binding with mAbs recognizing the N-terminal ECD. 
Comparison of binding sites of RSPO1 and anti-LGR6 antibodies on LGR6 
The N-terminal ECD of the LGR family is reported to be a binding region with respect to its ligands, 
RSPOs. Therefore, we analyzed whether anti-LGR6 mAbs inhibited the binding of RSPO1. 
Recombinant human RSPO1 with a C-terminal myc-His tag (RSPO1- yc-His) was prepared, and 
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the binding of RSPO1-myc-His to LGR6 and to LGR5 was analyzed by using Ba/F3 transfectants. 
RSPO1-myc-His bound to LGR6_Ba/F3 and LGR5_Ba/F3 in a dose-dependent manner, but did not 
bind to parent Ba/F3 cells (Fig. 5A). For validation of the assay system, we employed anti-LGR5 
mAb 2L36 because its epitope is close to the binding site of RSPO1 (20). As expected, 2L36 
dose-dependently blocked RSPO1 binding (Fig. 5B). Then we analyzed whether the binding of 
RSPO1 to LGR6 was blocked by anti-LGR6 antibodies. Monoclonal antibodies 43A6 and 43D10, 
which recognize the N-terminal ECD, competed with RSPO1-binding in an antibody dose-dependent 
manner (Fig. 5C). On the other hand, 43A25, which recognizes the 7TM domain of LGR6, did not 
inhibit RSPO1-binding. 
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Discussion 
It is commonly thought to be difficult to generate antibodies against multi-pass membrane proteins 
that are expressed at low levels, such as GPCRs, including those of the LGR family (18, 19). We 
have sought to generate mAbs against the LGR family that are suitable for use in flow cytometry, 
and successfully obtained anti-LGR5 mAbs in a previous study (20) and anti-LGR6 mAbs in this 
study. For immunization, we performed DNA immunization followed by whole-cell immunization 
in order to obtain antibodies that recognized the native conformational epitope of LGR6 which 
contains complicated LRR and 7TM structures. For screening of hybridomas, ELISA using 
recombinant proteins or peptides is generally preferred for its high throughput and sensitivity. 
However, in our experience, ELISA screening is not suitable for obtaining antibodies against native 
forms of target molecules. Therefore, we chose to use flow cytometry screening using 
LGR6-expressing transfectants. As a result, we successfully obtained antibodies recognizing the 
native form of LRR and 7TM regions of LGR6. 
An important issue with respect to this immunization and screening method was the 
establishment of transfectants that express sufficient amounts of antigen. To obtain such 
transfectants, we introduced LGR6 cDNA into several cell lines, and found that transfectants highly 
expressing LGR6 could be generated with Ba/F3 cells but not with CHO or HEK293 cells. The 
reason is currently unclear; however, it has been reported that Ba/F3 cells have been utilized as a 
host adequate for heterologous expression of functional GPCR (27-29) and are superior to CHO cells 
in some cases (27). 
The antibodies we obtained in the current study are expected to be utilized in various 
experiments to understand the biology of LGR6-positive cells in humans. Since LGR6 is expected to 
be expressed in stem cells, LGR6-positive cells might be rare in organs. By using the LGR6 
antibodies applicable to flow cytometry, it would be possible to analyze percentages of 
LGR6-positive cells, as well as their biological nature and gene expression profiles, by cell sorting. 
In addition, as shown in Figure 5C, mAbs 43A6 and 43D10 competitively blocked the binding of 
RSPO1 to LGR6. Although it is not yet confirmed whether these mAbs inhibit the RSPO signal 
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transmission in cells, the antibodies might be useful for understanding LGR6-dependent signaling in 
stem cells and cancer cells. Immunohistochemical analysis would also useful to understand the 
localization of LGR6-expressing cells in organs and tissues, but unfortunately, we could not obtain 
antibodies suitable for use in immunohistochemical analysis. Generation of such antibodies is 
expected in further studies. 
The results of the competition analyses suggest the region of LGR6 that binds to RSPO1. In the 
case of LGR4 and LGR5, crystal structure analysis has shown that RSPO1 recognizes LRR3 to 
LRR9 of the N-terminal ECD (30-33). But the binding region of LGR6 has not yet been reported. 
Here, anti-LGR6 antibodies 43A6 and 43D10 recognized the N-terminal ECD of LGR6 and blocked 
RSPO1 binding to LGR6. These findings suggest that RSPO1 binds to LGR6 via its N-terminal LRR 
domain, similarly to LGR4 and LGR5. 
In the skin, LGR6-positive cells differentiate to all kinds of skin cells which constitute the 
epidermis, such as skin, hair follicles, sebaceous glands, and interfollicular dermis (9). With respect 
to regenerative medicine in dermatology, the application of LGR6-positive stem cells is considered 
for the treatment of skin injuries (34-38). In this study, we generated anti-human LGR6 antibodies 
able to be used in flow cytometry and for immunoblot analysis. We expect that these antibodies will 
contribute to expanding our knowledge of the biology of LGR6-positive cells in regenerative 
medicine as well as in oncology. 
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Figure Legends 
Figure 1. Flow cytometric analysis of anti-LGR6 mAbs 
(A) Binding specificity was evaluated with HA-LGR4, LGR5, and LGR6-transfected Ba/F3 by flow
cytometry. Two µg/mL of anti-LGR6 mAbs (black line) or control isotype mAb (black shading)
were reacted with HA-LGR4, LGR5, LGR6-transfected Ba/F3, or parent Ba/F3 (results are
mean ± SD., n=3). As a control, 2L36 (for LGR5) (20) and HA-7 (for HA-LGR4) were used.
Binding was detected by PE-conjugated anti-mouse antibody.
(B) Dose-dependent binding was evaluated with LGR6_Ba/F3 (left) and parent Ba/F3 (right). Cells
were incubated with the indicated concentrations of 43A6 (closed triangles), 43A25 (closed
squares), and 43D10 (open circles).
Figure 2. Detection of LGR6 endogenously expressed on the cell surface in cancer cell lines. 
(A) The LGR6 mRNA expression levels of nine cell lines were determined by real-time PCR.
Relative expression level was calculated by normalizing with beta-actin.
(B) AsPC-1 and SW620 were incubated with 10 µg/mL of anti-LGR6 mAbs (black line) or control
isotype mAb (black shading) and analyzed by flow cytometry.
(C) siRNA against LGR6 (si-LGR6) or negative control (si-ctrl) were introduced to AsPC-1 cells by
lipofection. After 2 days, cells were collected and binding activities of anti-LGR6 mAbs (black
line) or control isotype mAb (black shading) were analyzed.
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Figure 3. Immunoblot analysis of anti-LGR6 mAb 
Whole-cell lysate of HA-LGR4-, LGR5-, and LGR6-transfected Ba/F3 cells and parent Ba/F3 cells 
was immunoblotted using 5 µg/mL of 43A25 as described in Materials and Methods. The expression 
of LGR5 and LGR4 of the transfectants was confirmed by anti-LGR5 mAb 2U1E-1 and anti-HA tag 
antibodies, respectively. Anti-beta actin antibody was used as control. 
Figure 4. Epitope analysis of anti-LGR6 mAbs 
(A) Full-length LGR6 or LGR6 ∆1–444 was expressed by 293F cells using the FreeStyle expression
system as described in Materials and Methods. The binding activity of anti-LGR6 mAbs was
analyzed by flow cytometry. Histograms show binding of anti-LGR6 mAbs (black line) or
control isotype mAb (black shading).
(B) Competition assays performed by flow cytometry. LGR6-transfected Ba/F3 cells were incubated
with unlabeled anti-LGR6 mAb (black line) or control IgG (gray shading) followed by
Alexa-488–labeled mAb. Histograms of cells not treated with antibodies are indicated by black
shading.
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Figure 5. Competitive activities of mAbs on RSPO1 binding to LGR6 
(A) LGR6-transfected Ba/F3 (closed squares), LGR5-transfected Ba/F3 (open circles), and parent
Ba/F3 (closed triangles) were incubated with the indicated concentrations of recombinant
RSPO1-myc-His. RSPO1 binding was detected by flow cytometry using anti-myc tag antibodies
(results are mean ± SD, n=3).
(B) LGR5-transfected Ba/F3 cells were incubated with 2L36 (closed diamonds) or control IgG
(closed circles), followed by 2 µg/mL of RSPO1-myc-His, and RSPO1 binding was analyzed by
flow cytometry.
(C) LGR6-transfected Ba/F3 cells were incubated with 43A6 (closed triangles), 43D10 (open
circles), 43A25 (closed squares), or control IgG (open squares) and RSPO1 binding was
analyzed by flow cytometry.
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It is ideal for the target antigen of a cytotoxic therapeutic
antibody against cancer to be cancer-speciﬁc, but such anti-
gens are rare. Thus an alternative strategy for target selec-
tion is necessary. Desmoglein 3 (DSG3) is highly expressed
in lung squamous cell carcinoma, while it is well-known that
anti-DSG3 antibodies cause pemphigus vulgaris, an autoim-
mune disease. We evaluated DSG3 as a novel target by se-
lecting an epitope that exerts efﬁcacy against cancer with no
pathogenic effects in normal tissues. Pathogenic anti-DSG3
antibodies induce skin blisters by inhibiting the cellcell
interaction in a Ca2+-dependent manner. We screened
anti-DSG3 antibodies that bind DGS3 independent of
Ca2+ and have high antibody-dependent cell cytotoxicity
(ADCC) activity against DSG3-expressing cells. These se-
lected antibodies did not inhibit cellcell interaction and
showed ADCC activity against squamous cell carcinoma
cell lines. Furthermore, one of the DSG3 antibodies
showed anti-tumour activity in tumour mouse models but
did not induce adverse effects such as blister formation in
the skin.Thus itwas possible to generate an antibodyagainst
DSG3by using an appropriate epitope that retained efﬁcacy
with no pathogenicity. This approach of epitope selection
may expand the variety of druggable target molecules.
Keywords: DSG3; epitope; monoclonal antibody;
pemphigus vulgaris; squamous cell carcinoma.
Abbreviations: ADCC, antibody-dependent cell cyto-
toxicity; DSG3, desmoglein 3; FACS, ﬂow cytometry;
mAb, monoclonal antibody; PV, pemphigus vulgaris;
SCC, squamous cell carcinoma.
Therapeutic antibodies are being actively researched and
used to treat an increasing number of diseases, including
cancer (1). Therapeutic antibodies for cancer are now
available with neutralizing, antibody-dependent cellular
cytotoxicity (ADCC) and complement-dependent
cytotoxicity (CDC) functions (26). Technologies for
producing low-fucosylated or defucosylated antibodies
that have enhanced ADCC have been established and
applied to therapeutic antibodies (79). The ideal
target molecule for a cytotoxic antibody is a cancer-
speciﬁc antigen, but although research has focused on
searching for such a target, almost no cancer-speciﬁc
antigens have been discovered (10). Thus, it may be
necessary to discover novel therapeutic antibodies by
an alternative strategy that involves selecting an anti-
gen with relatively high expression in cancer compared
with normal tissue and designing an antibody with
the appropriate anti-cancer functions against that
antigen.
Desmoglein-3 (DSG3) is expressed in normal squa-
mous epithelia and overexpressed in squamous cell car-
cinoma (SCC) of the lung (1114). However, DSG3 is
a molecule associated with pemphigus vulgaris (PV), a
severe autoimmune blistering disease affecting skin
and mucosa, and it is known that anti-DSG3 autoan-
tibodies are involved in the onset of the disease
(15, 16). Different disease states are induced according
to the different recognition sites of the anti-DSG3 anti-
bodies. Evidence of this is that the most severe disease
state is induced by antibodies that recognize the inter-
action sites of the EC1-EC2 domains at the N-terminal
of DGS3, whereas antibodies with other recognition
sites are not associated with pathogenic states
(1719). Because the evidence from PV suggests that
there is a large difference in biological reaction accord-
ing to the recognition site of an autoantibody, we
hypothesized that selecting the antibody epitope care-
fully would make it possible to develop a novel antic-
ancer antibody applicable for SCC that avoids the
pemphigus pathogenesis.
Here we show that we have obtained an anti-mouse
DSG3 monoclonal antibody (mAb) with therapeutic
potential and have evaluated whether its pathogenic
activity had been successfully separated from its antic-
ancer activity. Furthermore we have attempted to gen-
erate an anti-human DSG3 mAb with the same
characteristics.
Materials and Methods
Human clinical samples
The tissues evaluated in the current study are from the tissue library
at PharmaLogicals Research Pte. Ltd. (PLR, Singapore) (20). The
tissues examined in the current study included six cases of SCC (lung
2, skin 3 and uterus 1) and six cases of lung adenocarcinoma. The
surgically excised tissues were provided by patients that gave their
informed consent, as approved by the ethical committee at PLR in
Singapore.
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Animals
Dsg3 (-/-) mice (B6; 129X1-Dsg3tm1Stan/J) were purchased from
Jackson Laboratory and bred at Charles River Laboratories
Japan. Severe combined immunodeﬁcient (SCID) mice (C.B-17/lcr-
scid Jcl) were purchased from CLEA Japan. MRL/lpr mice (MRL/
MpJ-Tnfrsf6lpr/Crlj) and Balb/c mice (BALB/cAnNCrlCrlj) were
purchased from Charles River Laboratories Japan. Care and use
of animals used in this study was in accordance with the
Guidelines for the Care and Use of Laboratory Animals under the
approval of the Institutional Animal Care and Use Committees at
The University of Tokyo and Chugai Pharmaceutical Co., Ltd.
Immunizations were performed in the experimental animal facility
at The University of Tokyo. Mouse xenograft experiments were per-
formed at Chugai Pharmaceutical Co., Ltd.
Cells
Chinese hamster ovary (CHO) cell line DG44, mouse B cell line Ba/
F3 or human lung SCC cell lines HARA and A431 were purchased
from Invitrogen, Riken Bioresource Center, and Health Science
Research Resources Bank, respectively. Human NK cell lymphoma
cell line NK-92, tongue SCC cell lines SCC-15 and mouse myeloma
P3-X63Ag8U1 (P3U1) were obtained from the ATCC. Mouse lung
SCC cell line LC-12 was purchased from NCI and maintained by
subcutaneously inoculating minced tissues into Balb/c mice. Normal
human keratinocyte CryoNHEK-Neo and mouse keratinocyte
MPEK-BL6 were purchased from Lonza and CELLnTEC. GDP-
fucose transporter (GFT) (-/-) CHO cell was obtained from Chugai
Pharmaceutical Co., Ltd. (7). All cell cultures were conducted ac-
cording to the manufacturers’ instructions. Most of the reagents for
cell culture were purchased from Invitrogen. Culture conditions are
described in Supplementary Data.
DNA
Full-length cDNA of human DSG3 (RefSeq: NM_001944) was ob-
tained by PCR ampliﬁcation from human small intestine Marathon-
Ready cDNA (Clontech). In the same manner, mouse DSG3 cDNA
(RefSeq: NM_030596) was cloned from mouse E17 cDNA
(Clontech). Mouse FcgRIIIa (CD16) (RefSeq: NM_010188) was
cloned from mouse spleen cDNA (Clontech).
Each cDNA was cloned into the mammalian expression vector,
pMCN (pMCN/human DSG3, pMCN/mouse DSG3). pMCN is
vector driven under the promoter of mouse CMV and is selected
with the neomycin-resistance gene.
Establishment of DSG3-expressing stable cell lines in
CHOandBa/F3andNK92cell lines for theADCCassay
All transfections were carried out by electroporation with BioRad
GenePulser, and stable transfectants were selected in the medium in
the presence of geneticin (Invitrogen). Next, cell lines derived from
single cells that had been clonally expanded were obtained by the
limiting-dilution method. Electroporation was conducted under con-
ditions of 1.5 kV, 25 mF for CHO DG44, 260V, 1050 mF for Ba/F3
and 200 kV, 975 mF for NK92. The cells were suspended in phos-
phate-buffered saline (PBS) (-) at a concentration of 1107 cells/ml,
and were transfected with 1025 mg of plasmid DNA. The cell sur-
face expression of mouse or human DSG3 in the transfected cells
was conﬁrmed by ﬂow cytometry (FACS) with AK23 antibody.
CHO DG44 transduced with mouse or human DSG3 cDNA was
designated as mouse DSG3/DG44 or human DSG3/DG44, respect-
ively. The Ba/F3 transfectants were designated as mouse DSG3/
BaF3 and human DSG3/BaF3.
To establish a stable assay for ADCC activity, NK92 expressing
mouse FcgRIIIa (mFcgRIIIa-NK92) was established as a cell line
and incorporated as effector cells. Mouse FcgRIIIa was expressed as
a chimeric protein comprising the extracellular domain of mouse
FcgRIIIa (aa 1-212) fused to the transmembrane domain and the
cytoplasmic domain of human FcgRIIIa (aa 207-254). The cells were
clonally expanded by selecting in 500mg/ml of geneticin.
Generation of recombinant DSG3 proteins
Soluble mouse DSG3-His proteins were expressed in DG44 and af-
ﬁnity puriﬁed from the supernatants of the transfectants with His-
Trap column (GE Healthcare).
Soluble human DSG3 was expressed as sDSG3-mIgG2aFc com-
posed of the extracellular domain of human DSG3 (aa 1-616) and
the Fc portion of mouse IgG2a, and was puriﬁed with HiTrap
Protein G HP column (GE Healthcare) and eluted with 0.1M
Glycine-HCl (pH 2.7). The eluate was gel-ﬁltrated with Superdex
200HR 10/30 (GE Healthcare).
Glutathione S-transferase (GST)-human DSG3 fusion protein
(GST-hDSG3) was expressed in Escherichia coli as a fusion of
GST and 125 aa of human DSG3 (aa 491-615) with His-tag. GST-
hDSG3 was puriﬁed with His-Trap column (GE Healthcare) for use
as an antigen for ELISA.
Immunohistochemical (IHC) analysis of human DSG3
in clinical samples
Human tissues were ﬁxed in 4% paraformaldehyde upon collection,
and embedded in parafﬁn by the AMeX method as described previ-
ously (21, 22). Thin sections were prepared at a thickness of 35 mm
for histology and IHC. IHC staining for human DSG3 in human
tissues was performed using the following method. A monoclonal
mouse anti-human DSG3 antibody (Clone 5G11, Zymed) was
applied as the primary antibody. The tissues were stained by an
indirect immunoperoxidase method using the Ventana HX
Discovery System (Ventana Medical Systems). Brieﬂy, the slides
were de-waxed and treated with protein block (Dako Cytomation)
to reduce non-speciﬁc staining and 3% H2O2 in methanol to block
endogenous peroxidase. After incubation with the primary antibody
and Discovery Universal Secondary Antibody (Ventana Medical
Systems), streptavidin conjugated to horseradish peroxidase
(Ventana Medical Systems) was applied and the reaction visualized
with a diaminobenzidine solution (Ventana Medical Systems). The
slides were counterstained with haematoxylin and coverslipped. The
slides were read under a light microscope.
The slides were read for staining frequency (positive percentage to
all tumour cells), and staining intensity (scores: 0, negative; 1, very
weak; 2, weak; 3, moderate; 4, strong). The staining score was cal-
culated by adding up the product of staining frequency to intensity
scores.
Generation of anti-mouse DSG3mAbs
mAbs against mouse DSG3 were generated by DNA immunization.
A plasmid DNA expressing full length mouse Dsg3 was inoculated
into the skin of the abdomen of Dsg3-knockout (KO) mice using
Helios Gene Gun (BioRad) followed by intravenous injection of
mouse DSG3/DG44 cells as a booster immunization. At 4 days
after the last immunization, splenocytes were isolated and fused
with mouse myeloma P3U1 by the general polyethylene glycol
method with PEG1500 (Roche Diagnostics) (23). The resulting
hybridomas were selected by culturing in hypoxanthine/aminop-
terin/thymidine (HAT) medium containing RPMI-1640 medium
with 10% FBS, 1-fold concentration of HAT media supplement
(Sigma) and 0.5-fold concentration of BM-combined H1
Hybridoma cloning supplement (Roche Diagnostics). The culture
supernatants were screened for their ability to bind to mouse
DSG3 by FACS with mouse DSG3/DG44. Positive hybridomas
were subcloned by the limited-dilution method. We selected 34
FACS-positive clones, measured their ADCC activity and further
selected 12 candidates with strong ADCC. The 12 hybridomas,
1-2, 18-1, 33-1, 32-2, 29-2, 10-2, 20-1, 37-1, 5-1, 39-2, 19-1 and
40-2 were cultured in the medium containing HAT medium supple-
mented with Ultra low IgG FBS (Invitrogen), and mAbs were pur-
iﬁed by HiTrap Protein G column (GE Healthcare). Isotyping was
carried out with IsoStrip Mouse Monoclonal Antibody Isotyping
Kit (Roche Diagnostics).
Generation of anti-human DSG3mAbs
Anti-human DSG3 mAbs were generated by immunizing MRL/lpr
mice and Balb/c mice of 78weeks old. At the ﬁrst immunization,
100 mg of soluble human DSG3 (sDSG3-mIgG2aFc) was mixed with
complete Freund’s adjuvant (Beckton Dickinson) and was inocu-
lated subcutaneously. Two weeks later, 50 mg of sDSG3-mIgG2aFc
was mixed with incomplete Freund’s adjuvant and was inoculated
subcutaneously. At 1 week intervals, booster immunization was per-
formed two to four times, and a ﬁnal immunization was carried out
by injecting 50 mg of the same protein into the tail vein. At 4 days
after ﬁnal administration, splenocytes were isolated and fused with
S.-I. Funahashi et al.
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P3U1 by the conventional method. The hybridoma supernatant
was screened for binding activity to human DSG3 by FACS
with human DSG3/DG44. Positive hybridomas were cloned by the
limited-dilution method to establish monoclonal antibodies speciﬁc
for human DSG3. Of the antibody clones, DF366 was selected as the
mAb with the strongest ADCC activity.
FACS
Binding afﬁnity of mAbs to the antigens was analysed as described
previously (24, 25). Brieﬂy, Ba/F3 or DG44 transfectants were incu-
bated with mAb diluted to appropriate concentrations for 1 h on ice,
and then with FITC-labelled anti-mouse IgG for 30min on ice. After
reaction, the cells were analysed by FACS on a FACSCalibur ﬂow
cytometer (Beckton Dickinson).
In general, antibodies that induce PV-like states are known to
show Ca2+-dependent binding to mouse DSG3. Thus to select anti-
bodies with no pathogenic activity, we screened mAbs by evaluating
their Ca2+ independent binding activity. The mAbs were analysed as
with 1mM or without Ca2+ and 5mM EDTA by FACS.
In the case of LC-12 cells, the tumour tissue was resected and
disaggregated into a single cell suspension by treatment with
Dispase II (Roche Diagnostics) at 37C for 20 h.
ELISA
For GST-DSG3 ELISA, GST-hDSG3 protein was coated onto the
microtiter plate at a concentration of 1mg/ml, and blocked with 1%
BSA. Then anti-human DSG3 antibodies were incubated with GST-
hDSG3. The bound antibodies were detected with alkaline phosphatase
(AP)-conjugated goat anti-mouse kappa antibody (Southern Biotech).
In order to classify the antibodies to subgroups by binding regions
the competitive ELISA was performed as follows. After preincuba-
tion with non-labelled antibody (test antibody), biotin-labelled anti-
body was added, then the binding inhibition by test antibody was
measured to classify the binding region. Anti-human DSG3 mAbs
DF029, DF129, DF131, DF132, DF138, DF187 and DF269 were
biotinylated. Biotinylation was conducted with a biotin labelling kit
(Roche Diagnostics). The reaction was performed as reported before
(26). Brieﬂy, sDSG3-mIgG2aFc were bound onto anti-mouse IgG2a
antibody-precoated microtiter plate. Then test antibodies were incu-
bated at room temperature for 1 h, followed by incubation with
biotinylated antibodies. After washing, the binding of biotinylated
antibodies was detected with AP-conjugated streptavidin (Zymed).
The mAbs with 90% of binding inhibition were classiﬁed as antibo-
dies with the same binding region.
Generation of ADCC-enhanced antibody
Mouse mAbs were genetically engineered to produce antibodies of
the IgG2a isotype. Total RNA was extracted from the hybridoma
with the RNA easy plant mini kit (QIAGEN), and the genes encod-
ing the mAb were ampliﬁed by reverse transcription-PCR (RT-PCR)
using the method described previously (26). PCR products were
cloned into pGEM-T Easy vector (Promega) and nucleotide se-
quences were determined.
A chimeric anti-DSG3 antibody, in which the mouse variable re-
gions were linked with the mouse IgG2a and kappa constant regions
or human IgG1 and kappa regions, was constructed. The light and
heavy chain expression vectors were co-transfected into CHO DG44
cells and selected with geneticin. Screening clones of the well-
expressed antibodies by ﬂow cytometry with mouse DSG3/DG44
or human DSG3/DG44, we puriﬁed the chimeric antibodies with a
HiTrap ProteinG column. Anti-mouse DSG3 mAb 18-1 with a
mouse IgG2a isotype was designated as 18-1m, and anti-human
DSG3 mAb DF366 as DF366m. Anti-human DSG3 mAb DF366
with a human IgG1 isotype was designated as DF366c.
Defucosylated antibody 18-1m or DF366m was expressed in GFT
(-/-) CHO cells with disrupted GFT alleles of GFT gene (7) and
designated as df-18-1m or df-DF366m.
Analysis of cell-cell dissociating activity
Cellcell dissociating activity of mAbs was analysed by the keratino-
cyte dissociation assay described previously (27). Normal mouse
keratinocytes (MPEK-BL6) or human keratinocytes (CryoNHEK-
Neo) were used. When cells reached conﬂuence, the culture medium
was changed to the same medium containing 1.2mM Ca2+. Then
antibody was added to a ﬁnal concentration of 10 mg/ml. After
incubation at 37C overnight, Staphylococcal exotoxin, exfoliative
toxin A (ETA) (Toxin Technology) was added at 0.5 ug/ml for over
2 h to disrupt DSG1. Cells were washed with HBSS twice, and
incubated with Dispase (Roche Diagnostics) for 30min to detach
the monolayer sheets. The detached cells were further mechanically
dissociated by pipetting. After pipetting, the cells were observed by
light microscopy.
AK23 antibody, which was derived from an active PV mouse
model (27) and is known to inhibit cellcell interaction, was used
as the positive control for this assay.
Mouse IgG2a mAb AK23m was generated by a similar process to
18-1m, using a published sequence of the variable region of mAb
AK23, which induces PV (19, 28).
Determination of ADCC
ADCC activity of mAbs was determined as follows. Tumour cells
were cultured in RPMI1640 with penicillin/streptomycin and 10%
FBS (RPMI medium). About 1106 cell of mouse DSG3/BaF3 or
human DSG3/BaF3 was suspended in 200 ml of RPMI medium with
3.7 MBq of 51Cr-sodium chromate (GE Healthcare) and incubated
in 5% CO2, at 37
C for 1 h. Cells were washed with RPMI medium
adjusted to a concentration of 2105 cells/ml and dispensed at 50 ml
into a 96-well U-bottomed plate. Then 50 ml of antibody solution
was added to each well, and the plates were incubated for 15min
at room temperature. Next 5104 cells of mFcgRIIIa-NK92 (in the
case of mouse IgG2a chimeric antibodies) or NK92 (in the case of
human IgG1 chimeric antibodies) were added as effector cells. The
tumour cells were further incubated at 37C for 4 h in 5% CO2.
100 ml of supernatants were collected from each well and radioactiv-
ity in the supernatants was measured with a gamma counter (1480
WIZARD 300, Wallac). 51Cr release was calculated based on the fol-
lowing formula:
Specific 51Crrelease ð%Þ ¼ ðA CÞ=ðB CÞ  100
where A is the 51Cr release of each well (cpm), B is the mean 51Cr
release for 50 ml of cells incubated in 150ml of 2% Nonidet P-40
(Nakalai Tesque) and C is the mean 51Cr release for 50 ml of cells
incubated in 150ml of RPMI medium (cpm). All experiments were
conducted in duplicate. Median value and standard deviation were
calculated. Mouse IgG2a (Becton Dickinson) was used as a negative
control antibody.
Determination of anti-tumour efficacy and toxicity
in vivo
The anti-tumour activity of anti-mouse DGS3 antibodies was eval-
uated using a syngeneic mouse model as follows. Balb/c mice were
inoculated subcutaneously with approximate 3 mm3 cubes of LC-12
tumour tissue. Mice were divided into three groups one day after
tumour inoculation. Each group consisted of 10 mice, and 18-1m, df-
18-1m (10mg/kg) or vehicle (PBS) was administered intravenously
on days 1, 8 and 15. Tumour volume and body weight were mea-
sured twice a week.
Anti-tumour efﬁcacy and toxicity were evaluated in human SCC
xenograft models. About 1107 cells of HARA and A431 cells sus-
pended in HBSS were inoculated and approximate 3 mm3 cubes of
SCC-15 tumour tissue were inoculated subcutaneously into SCID
mice. When the mean tumour volumes reached 100 mm3, 80 mm3
and 120 mm3, respectively, the mice were subjected to the study.
Seven and ﬁve SCID mice per group (HARA and A431) were
dosed intravenously with 10mg/kg of mAb (df-DF366m) or with
vehicle (PBS) once a week. Four SCID mice per group (SCC-15)
were dosed intraperitoneally with 10mg/kg of mAb (df-DF366m)
or vehicle (PBS) once a week for 5 weeks. Tumour volume and
body weight were measured twice a week. Tumour volume was
determined with the formula: ab2/2 (mm3), where a and b are the
longest and shortest diameters, respectively. Statistical analysis was
conducted with the Dunnett’s test (LC-12) and t-test (HARA, A431
and SCC-15) using the SAS statistical package software (SAS
Institute). Statistical signiﬁcance was judged at P50.05.
At necropsy, the animals were euthanized by exsanguination from
the abdominal artery under deep isoﬂurane anaesthesia. The small
intestine, colon, liver, kidney, spleen and thymus, and tissues with
squamous epithelia (skin, oral mucosa, oesophagus and foresto-
mach) were ﬁxed in 10% neutral-buffered formalin, and embedded
into parafﬁn by a routine method. Thin sections were prepared at a
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thickness of 5 mm, stained with haematoxylin and eosin, and read
under a light microscope. Inﬂammatory cell inﬁltration was evalu-
ated pathologically by certiﬁed pathologists.
Results
DSG3 expression in human tissues
Six out of six cases of SCC in various organs were
positive for DSG3 (Fig. 1A). The staining of a repre-
sentative sample is shown in Fig. 1B (left panel). In 5/6
cases, the staining score was higher than 200, and two
of the lung SCC cases had scores higher than 300. In
contrast, only 1/6 cases was positive for adenocarcin-
oma in the lung, and the score was notably lower than
lung SCC. In non-cancerous tissue, the epidermis in
tumour adjacent skin was positive in 2/2 cases
(Fig. 1A). DSG3 expression was observed from the
basal cell layer to prickle cell layer (Fig. 1B, right
panel). Epidermal hyperplasia was present, but the
staining score was lower than 200 and tended to be
lower compared with SCC.
Generation of anti-mouse DSG3mAbswith ADCC
activity
To conﬁrm the proof of concept in non-clinical
models, we attempted to generate an anti-mouse
DSG3 mAb that has anti-tumour activity by ADCC
to SCC, but with no cellcell dissociating effects in
keratinocytes that cause PV (Fig. 2A).
By FACS with hybridoma supernatants, 34 clones
with robust binding activity were selected. Next,
ADCC activity was measured with an antibody con-
centration of 1 mg/ml, and 12 clones with the strongest
ADCC activity were further selected (Fig. 2B).
Selection of cloneswith no PV-like effects by
evaluation of Ca2+-dependent binding and
the cellcell dissociation assay
The above-mentioned 12 clones were examined for Ca2+-
dependent binding to mouse DSG3 by FACS. As it is
well-known that pathogenic anti-DSG3 antibodies like
AK23 recognize an epitope with a calcium-dependent
conformation, we screened the antibodies for calcium de-
pendency (28, 33). Three clones, 18-1, 37-1 and 40-2,
bound to mouse DSG3 equally with and without Ca2+,
and were determined as having Ca2+ independent bind-
ing activity (Fig. 2C). Other clones bound weakly to
mouse DSG3 when Ca2+ was not present, and were
determined as having Ca2+-dependent binding activity.
Of the three clones with Ca2+ independent binding
activity, clone 18-1 had the highest afﬁnity, and so was
selected for further evaluation. In order to ascertain
the potential to induce PV, cellcell dissociating activ-
ity in a mouse keratinocyte sheet was tested. The test
was designed to compare the cellular effects induced by
a difference only in antigen binding while the Fc func-
tion remained the same.
18-1 and AK23 were genetically engineered into
mouse IgG2a-type chimeric antibodies 18-1m and
AK23m, and were subjected to the assay. 18-1m did
not induce keratinocyte dissociation, while the positive
control antibody AK23m did. This was thought to
show that 18-1m was not pathogenic (Fig. 2D).
Enhancement of ADCC activity by defucosylation of
antibody
As reported previously, an antibody produced by GFT
(-/-) CHO cells is mainly a fucose-free oligosaccharide
(7), a so-called defucosylated antibody, which binds
strongly to mouse FcgRIIIa and thus exhibits much
enhanced ADCC. A defucosylated antibody, df-18-1m,
induced ADCC activity that was comparable to a
10-fold concentration of 18-1m. Thus we conﬁrmed
that defucosylation further enhanced ADCC (Fig. 2E).
Anti-tumour efficacy and toxicity of 18-1m, df-18-1m
antibodies in vivo
As we were able to generate an anti-mouse DSG3 anti-
body with the potential of anti-tumour ADCC activity
but no pathogenic activity to normal tissues, we exam-
ined the proof of concept in a syngeneic mouse model
of a mouse lung SCC cell line, LC12.
A
B
Fig. 1 Expression of DSG3 in human tissues. (A) DSG3 was ex-
pressed frequently in SCC of various organs compared with adeno-
carcinoma of the lung. Tumour-adjacent skin also expressed DSG3.
G1G3, histology grade; CIS, carcinoma in situ; Th, thickening of
epidermis; SCC, squamous cell carcinoma; AC, adenocarcinoma;
TA, tumour-adjacent tissue; Lu, lung; Sk, skin; Ut, uterus. (B)
Images of IHC staining in SCC of the lung (left panel) and tumour-
adjacent skin (right panel). Labelled streptavidin-biotin method. E
presents epidermis. Bar = 100mm.
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After administering 18-1m or df-18-1m once a week
for 3weeks to LC12-inoculated mice, the body weight
of antibody-administered mice was slightly lower com-
pared with that of vehicle-administered mice at the end
of the study. However, there were no changes in the
general condition of mice in any of the groups and
there is no serious toxicity (Fig. 3A).
In contrast, the tumour volume was signiﬁcantly
lower antibody-administered groups compared with
the control group (Fig. 3B). Suppression of tumour
A
C
B
Fig. 2 Characterization of anti-mouse DSG3 mAbs. (A) Screening ﬂow for an anti-mouse DSG3 mAb. (B) Analysis of ADCC activity.
51Cr-labelled 1104 mouse DSG3/BaF3 cells were incubated with hybridoma supernatant at 1 mg/ml antibody for 15min. mFcgRIIIa-NK92
were added at E/T ratio = 5:1 and the cell suspensions were further incubated at 37C for 4 h. The radioactivity was measured with Gamma
counter. Speciﬁc 51Cr release was calculated. Mouse IgG2a was used as reference control. (C) Analysis of Ca2+-dependent binding activity to
mouse DSG3. Serial diluted mAbs were incubated with mouse DSG3/DG44. The binding activity to mouse DSG3 was measured with FACS
with EDTA (closed circle) or without EDTA (open circle). (D) Analysis of cellcell dissociating activity with mouse IgG2a type chimeric anti-
DSG3 18-1m. Cellcell dissociating activity with mAb 18-1m was analysed by keratinocyte dissociation assay (27). mAb AK23m was used as
positive control. (E) ADCC enhancement by defucosylated chimeric anti-DSG3. ADCC activity of 18-1m was compared. Mouse DSG3/DG44
was incubated with serial diluted antibody and mixed with mFcgRIIIa-NK92 as effector cells. ADCC activity was measured. Black circle: 18-1m,
grey circle: df-18-1m prepared with GFT (-/-) CHO cells.
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growth was marked in the df-18-1 group compared
with the 18-1m group. The number of cases with
tumour volumes of less than 3 mm3 or with no palp-
able mass of histologically detectable tumour cells was
1/10 in each of the control and 18-1m groups, but 6/10
in the df-18-1m group (Fig. 3C). Histopathologically,
single-cell necrosis of tumour cells and inﬂammatory
cell inﬁltration were observed in palpable tumours
of the 18-1m group. Similar changes were observed
in the palpable tumours of the df-18-1m group
(Fig. 3C and D).
There were no histopathological changes in tissues
containing squamous cells (skin, oral mucosa, oe-
sophagus and forestomach) and other tissues (intes-
tine, colon, liver, kidney, spleen and thymus).
Generation of anti-human DSG3 antibody
The results from the mouse studies showed the possi-
bility that antibodies with anti-tumour activity and no
PV-like pathogenic activity could be generated, so we
proceeded to generate an anti-human DSG3 antibody
with similar features.
A B
C D
Fig. 3 Results of anti-mouse DSG3 mAb administration in tumour-bearing Balb/c mice. Anti-mouse DSG3 mAb 18-1m and df-18-1m were
inoculated at 10mg/kg in LC12 syngeneic mouse model. Days of treatment with mAb are shown by arrows. (A) Body weight change.
(B) Tumour volume change. The mean for each group is shown for each time point. Bars indicate standard deviation of the mean. White circle,
control; grey circle, 18-1m; black circle, df-18-1m. *P50.05, compared with vehicle. (C) Histological examination of engrafted LC12 tumours.
The presence of tumour cells in the site of engraftment (upper left). Closed square, present; open square, absent. Changes related to the
pharmacological effects of the antibodies (lower left) are shown by severity of change: ±, very slight; +, slight; ++, moderate; +++, severe.
(D) Representative images of tumours in each group. Increased inﬂammatory cell inﬁltration and single-cell necrosis (arrow heads) were
observed in antibody administered tumours. The changes were noted around the interface (broken line) of the tumour mass (T) with surrounding
tissue. Bar = 100mm.
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The screening ﬂow in Fig. 4A shows how the anti-
body was selected. We immunized mice with human
sDSG3-mIgG2aFc protein, and established 86 hybri-
doma clones that were positive for activity against
human DSG3, from which clones with high afﬁnity
were selected by FACS. In general, the epitopes that
are contained in the membrane-proximal region of a
membrane protein tend to give high ADCC (26, 31), so
hDSG3 (aa 491-615, which is equivalent to the mem-
brane-proximal region) would be a candidate for an
ADCC epitope. Therefore, we added a GST-DSG3
ELISA to the screening to obtain an antibody that
would bind to a region that is safely distant from the
EC1-EC2 domains and would have higher ADCC.
To select clones that bound to a unique binding
region, we used a competition ELISA in the following
procedure. First, seven of the hybridoma clones that
gave no cross-reaction were chosen as competition
antibodies and were biotinylated. Then, the
competition ELISA divided the hybridoma clones
into six groups, and a representative clone from each
group was selected after evaluating the binding afﬁnity
by FACS and the ADCC. Chimeras of each of these
clones were generated with a human IgG1 Fc portion
to compare the cytotoxic effects in a clinically relevant
format.
Figure 4B summarizes the characters of the six rep-
resentative clones. Their ADCC was categorized into
two levels of activity: high (two clones) and middle
(four clones) (Fig. 4C). As expected, the binding re-
gions of the two clones with the strongest ADCC,
DF366 and DF378, were located between aa 491 and
615. There was no difference in binding afﬁnity of the
two clones with high ADCC (Fig. 4D).
From these results, DF366 was selected as the clone
with strongest ADCC activity and converted to a
mouse IgG2a subclass (designated as DF366m) to
evaluate cellcell dissociation activity in human
A B
C
E
D
Fig. 4 Characterization of anti-human DSG3 mAbs. (A) Screening ﬂow for an anti-human DSG3 mAb. (B) Classiﬁcation of mAbs with GST-
human DSG3 (aa 491-615) ELISA and competition ELISA. In GST-ELISA, dark grey indicates positive. In competition ELISA, dark grey
indicates >90% inhibition and light grey indicates >70% inhibition. Bio-(antibody number) indicates a biotinylated antibody. (C) ADCC
activity was measured as speciﬁc 51Cr release. Black circle, DF366c; grey circle, DF378c; white circle, DF347c; black triangle, DF151c; grey
triangle, DF364c; white triangle, DF050c. (D) Binding activity to human DSG3/DG44. Serial diluted antibody was incubated with human
DSG3/DG44, and binding activity was measured with FACS. Symbols are the same as (C). (E) Cellcell dissociation activity was analysed in
human keratinocytes. Mouse IgG2a chimeric antibody DF366m was compared with AK23m as a positive control.
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keratinocyte sheets. DF366m did not show cellcell
dissociation activity, while the positive control
AK23m antibody did (Fig. 4E).
Anti-tumour efficacy of anti-human DSG3mAbs
against SCC
ADCC activity of DF366m was compared with a defu-
cosylated antibody (df-DF366m) with mFcgRIIIa-NK92
as the effector cells. The anti-tumour effect of ADCC-
enhanced df-DF366m was evaluated in an in vitro
ADCC assay with human SCC cell lines HARA, A431
or SCC-15. The results showed that both DF366 and df-
DF366m have ADCC activity against human SCC cell
lines (Fig. 5A). df-DF366m showed strong ADCC activ-
ity even at concentrations that were several score times
lower than DF366m.
Next, the anti-tumour effect of df-DF366m was
investigated in vivo using xenograft models of HARA,
A431 and SCC-15. In all models, efﬁcacy of df-DF366m
was signiﬁcantly enhanced (Fig. 5B). Especially in SCC-
15, the tumour growth was completely inhibited.
Discussion
DSG3 has been reported to be highly expressed in lung
SCC both at mRNA and protein levels (16, 17, 29). We
examined the expression of DSG3 in SCC by IHC and
conﬁrmed that the expression was high, which was
consistent with the reported results, and thus we con-
sidered that DSG3 is a potential target for therapeutic
antibodies against SCC. On the other hand, DSG3 is
also expressed in normal squamous epithelium (16),
and autoantibodies against DSG3 cause PV, an
autoimmune disease that includes severe skin lesions,
such as blistering (30). Tsunoda et al. have also shown
that anti-DSG3 mAbs induced PV blisters in a passive
transfer assay with neonatal mouse (15). Because of
those results, we judged it necessary to avoid PV-like
pathogenic activity if we selected DSG3 as a target for
a therapeutic antibody. We generated anti-DSG3
mAbs to examine their potential as a therapeutic
antibody.
It is well-known that therapeutic antibodies can
induce biological effects by several mechanisms. To
attack cancer cells, a variety of modes of action have
been utilized: mAb with ADCC, CDC activity that
utilizes the host immune response, toxin-conjugated
antibodies that utilize antibodies as a drug delivery
system and so on (6, 10). The ADCC activity of an
antibody is considered to be dependent on the
amount of antigen available to induce host immune
response and cytotoxicity (7, 31, 32). In this study,
we have found that some SCC cases express higher
levels of DSG3 than non-tumour. Thus we hypothe-
sized that a mode of action via ADCC would be effect-
ive for obtaining tumour speciﬁcity.
In order to achieve our concept, it was thought ne-
cessary to generate an antibody with no PV-like patho-
genic activity. It has been reported that in the
pemphigus pathogenesis the neutralizing activity of pa-
tient pathogenic autoantibodies causes a disruption of
the DSG3-DSG3 adhesive interaction, and that subse-
quently destroys the epithelial cell structure (15). It is
also known that autoantibodies with a Ca2+-sensitive
epitope cause cellcell dissociation, and that these
antibodies recognize a Ca2+-dependent conformation
A
B
Fig. 5 Anti-tumour activity of defucosylated anti-human DSG3. (A) ADCC activity was measured with SCC cell lines. Bars indicate standard
deviation of the mean. HARA, human lung SCC; A431, human skin SCC; SCC-15, human tongue SCC. DF366m (white circle), df-DF366m
(black circle), control mIg2a (grey circle). (B) Each SCC cell line was inoculated s.c. in SCID mice. Mice were treated with mAb df-DF366m
(black circle) or vehicle, PBS (white circle) on the days indicated by arrows. Tumour volume was measured twice a week. Bars indicate standard
deviation of the mean. *P50.05, compared with vehicle.
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epitope that regulates cellcell adhesion function (33).
As epitope speciﬁcity is critical for PV activity, we con-
sidered it possible to add the ADCC function to an
antibody while avoiding PV activity by selecting an
appropriate epitope. Thus we attempted to obtain a
wide variety of antibodies for functional screening.
In order to generate a wide variety of antibodies we
utilized KO mice for immunization as described previ-
ously (34, 35). Additionally we applied a DNA immun-
ization method and were able to obtain a large number
of different antibodies. Next, we adopted functional
screening methods to select antibodies that have
ADCC activity, but do not cause PV-like action.
Conventional assay systems with mouse splenocytes
are known to yield inconsistent results between lots,
and the preparation is also a complicated process.
Thus we established an ADCC screening system with
the mFcgRIIIa-NK92 cell line that could stably meas-
ure ADCC activity. To screen for mAbs with no PV-like
effects, we tested binding to DSG3 in a Ca2+ independ-
ent manner by ELISA and FACS in the presence of a
Ca2+ chelating agent, EDTA. As a result we obtained
anti-mouse DSG3 antibodies with ADCC activity in
vitro, but no keratinocyte cellcell dissociation.
We investigated the binding region of these clones
by domain-swapped mutant analysis, and found that
the mouse clone 18-1 binds to a region in the cadherin
domains not EC1, while DF366 recognizes the mem-
brane-proximal region (data not shown). When screen-
ing for anti-human DSG3 antibodies, we could not
obtain antibodies that were cross-reactive to mouse
DSG3. Mouse and human DSG3 are very homologous
apart from their membrane-proximal regions, which
tend to contain binding regions that provide high
ADCC. When we screened for the anti-human DSG3
antibody, we aimed for an antibody that bound to a
region that induced higher ADCC and was safely dis-
tant from the EC1-EC2 domains. With this in mind,
we considered the best antibody against human DSG3
would be derived from a clone that bound to the prox-
imal region. We therefore used a competition ELISA
to classify the clones according to their binding regions
and then selected the antibody in each group with the
highest ADCC.
As ADCC activity and PV-like activity are different
modes of action, we considered that enhancing ADCC
would be an effective approach to improve anti-
tumour activity without causing a toxic effect to the
skin. To this end, we chose the mouse antibody that
had the highest ADCC activity and enhanced its
ADCC activity by changing to an IgG2a version (36,
37) and a defucosylated version of the antibody using
the GFT (-/-) CHO cells (7). Then, to test our hypoth-
esis in vivo, we evaluated the non-defucosylated and
defucosylated antibodies for anti-tumour activity and
PV-like pathogenic activity in a mouse model. In vivo
anti-tumour activity was observed with both antibo-
dies, but the enhanced ADCC activity did not lead to
additional weight loss or induction of severe toxicity,
such as patchy hair loss, oral erosion and death, which
are reported in mice dosed with PV-inducible anti-
DSG3 AK23 (38). In a preliminary study with another
mouse model, we observed minor, non-lethal changes
in the vaginal mucosa, and we are currently studying
the lesions in detail. From these results we judged that
the defucosylated antibody improved anti-tumour ac-
tivity, while the enhanced ADCC activity was not asso-
ciated with enhanced toxicity. The current results in
the mouse model strongly suggest that the neutralizing
activity that disrupts DSG3 adhesive interaction can
be separated from cytotoxicity by ADCC to DSG3-
expressing cells. Therefore DSG3 was thought to be
a suitable target for therapeutic antibody development.
Because the potential of DSG3 as a therapeutic target
was shown in a mouse model, we attempted to generate
an anti-human DSG3 antibody with similar characteris-
tics to the mouse antibody. We succeeded in generating
an antibody that binds to DSG3, with ADCC activity
in vitro, and no adhesive interference activity to keratino-
cytes. Defucosylated anti-human DSG3 antibody
showed anti-tumour activity against three differential
SCC cell lines in xenograft models. These results indicate
that it is possible to generate an anti-human DSG3 anti-
body with the same properties as our anti-mouse DSG3
antibody. It should be noted that effects in normal tis-
sues could not be evaluated in mouse xenograft models
with anti-human DSG3 antibody because the antibody
does not recognize mouse DSG3. To address these
issues, future toxicity studies will be necessary.
Ideally, therapeutic antibodies that function by cyto-
toxicity to cancer cells should target an antigen that is
tumour-speciﬁc with no expression in normal tissues.
However such tumour-speciﬁc antigens are very rare
(39). Here we show it is possible to develop novel anti-
tumour therapeutic antibodies even if the target mole-
cule is expressed in both tumour and normal tissues, by
carefully selecting the appropriate epitope and mode of
action. Such an approach may enable currently
undruggable targets to be targeted in the future.
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